Model-Based Meta-Analysis (MBMA) Archives | Page 2 of 5 | サターラ

Fact Sheet

ファーマコメトリクスによる医薬品開発の意思決定支援：モデルに基づくメタ解析（MBMA）

Whether you’re optimizing trial design or seeking strategic insights, Certara’s MBMA delivers the clarity and…

Certara2025年2月19日

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

Certara2025年1月9日

Publication

INTERCEPT-AD：アルツハイマー病による軽度認知障害または軽度認知症の被験者を対象とした、サビルネトゥグ静脈内投与のフェーズ1試験

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

Certara2025年1月8日

Poster

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

Certara2024年12月11日

Amgen

Case Study

MBMAを用いた仮想的な「直接比較試験」の実施

Osteoporosis is common in post-menopausal women. The long-term sequelae of osteoporosis include bone fractures, particularly…

Certara2023年4月21日

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

Certara2021年12月15日

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

Certara2019年12月19日

Publication

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…

Certara2018年6月2日

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Certara2018年2月15日

White Paper

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

Certara2017年8月24日

© 2025 Certara. All Rights Reserved. | 法務関連 | 個人情報保護

Powered by Translations.com GlobalLink Web Software